(Q39186942)

9 September 2017

Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study (English)

1 reference

9 September 2017

osteogenesis imperfecta

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26138583%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Mona S Aglan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26138583%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Mona Ibrahim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26138583%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Samia A Temtamy

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26138583%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

author name string

M Elnashar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26138583%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

R A S El Banna

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26138583%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

language of work or name

English

0 references

publication date

3 July 2015

1 reference

Osteoporosis International

9 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26138583%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26138583%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26138583%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

page(s)

81-92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26138583%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00198-015-3216-9

14 June 2020

exact match

0 references

cites work

Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

PPIB mutations cause severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome--osteogenesis imperfecta phenotypic spectrum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Nosology and classification of genetic skeletal disorders: 2010 revision.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Genetic heterogeneity in osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

A scoring system for the assessment of clinical severity in osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Recessively inherited forms of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Mutations in FKBP10 cause recessive osteogenesis imperfecta and Bruck syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Mutations in FKBP10 cause both Bruck syndrome and isolated osteogenesis imperfecta in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

A novel homozygous 5 bp deletion in FKBP10 causes clinically Bruck syndrome in an Indonesian patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Recent advances in osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Clinical review 1: Bisphosphonate use in childhood osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Mutations in WNT1 cause different forms of bone fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Current, new and future treatments of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Osteogenesis Imperfecta: update on presentation and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

21 January 2018

Osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Surgery versus surgery plus pamidronate in the management of osteogenesis imperfecta patients: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Response to zolendronic acid in children with type III osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Osteogenesis imperfecta: questions and answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Clinical and molecular analysis in families with autosomal recessive osteogenesis imperfecta identifies mutations in five genes and suggests genotype-phenotype correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Zoledronic Acid Treatment in Children with Osteogenesis Imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-015-3216-9

Cyclic Pamidronate Infusion for Neonatal-onset Osteogenesis Imperfecta

21 January 2018

1 reference

12 December 2020

Experience with bisphosphonates in osteogenesis imperfecta

1 reference

12 December 2020

Modern approach to children with osteogenesis imperfecta

1 reference

12 December 2020

First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI

1 reference

12 December 2020

Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2

1 reference

12 December 2020

Cyclic pamidronate therapy in children with osteogenesis imperfecta.

1 reference

12 December 2020

Acute phase response and mineral status following low dose intravenous zoledronic acid in children

1 reference

12 December 2020

Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment

1 reference

12 December 2020

Intravenous pamidronate treatment improves growth in prepubertal osteogenesis imperfecta patients

1 reference

12 December 2020

Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta

1 reference

12 December 2020